Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05028829Phase 2Recruiting

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

Role: lead

NCT04343976Phase 2Terminated

Pegylated Interferon Lambda Treatment for COVID-19

Role: lead

NCT03781726Phase 4Completed

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Role: lead

All 3 trials loaded